INDV — Indivior PLC Ordinary Shares
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
$34.87
+$0.31 (+0.90%)
Indivior PLC Ordinary Shares (INDV) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Joseph J. Ciaffoni, based in 10710 Midlothian Turnpike, North Chesterfield, VA, United States, 23235, with about 827 employees. Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Latest reported INDV revenue for 2025-09-30 was $314.0M. Net income was $42.0M. Revenue was up 4.0% from 2025-06-30 to 2025-09-30. INDV currently screens at market cap $4.48B and trailing P/E 19.5.
Use this INDV page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the INDV quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the INDV SEC filings page. Lician reads the product cache first so this HTML stays unique to Indivior PLC Ordinary Shares even when a live quote feed is slow.
About Indivior PLC Ordinary Shares
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
INDV Key Statistics
Market Cap
$4.48B
Volume
1.71M
Previous Close
$36.18
Day Range
$35.61 – $36.75
P/E Ratio
19.45
P/B Ratio
145.25
EPS
$0.02
Revenue
$1.19B
Net Income
$2.00M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+8.7%
Profit Margin
0.2%
Employees
827
INDV Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $1.19B | $1.09B | $901.00M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | $2.00M | -$129.00M | -$44.00M |
| EPS (Diluted) | $0.02 | -$0.94 | -$0.32 |
Total Assets
$1.32B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$319.00M
Operating Cash Flow
$36.00M
Free Cash Flow
$0.00
Indivior PLC Ordinary Shares Company Information
- CEO & Director
- Joseph J. Ciaffoni
- Headquarters
- 10710 Midlothian Turnpike, North Chesterfield, VA, United States, 23235
- Website
- www.indivior.com
- Phone
- 804 379 1040
- IPO / Founded
- 2014-12-29
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic